SCHEMBL6134078

SCHEMBL6134078

CC(C)n1nc(-c2cnc(N)nc2-c2ccccc2O)ccc1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.41
KMT2A Q03164 1/20 0.41
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
MAPT P10636 4/20 0.39
NPSR1 Q6W5P4 3/20 0.39
MAPK10 P53779 2/20 0.39
LMNA P02545 2/20 0.39
GAA P10253 1/20 0.39
LRRK2 Q5S007 1/20 0.39
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
PTK2B Q14289 1/20 0.37
NCOA1 Q15788 1/20 0.37
NCOA3 Q9Y6Q9 1/20 0.37
ADORA2A P29274 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134252 0.88 ADORA2A (0.38) LMNATP53ADORA2AADORA1SRC
SCHEMBL6134468 0.87 ADORA2A (0.37) MAPTADORA2AADORA1
SCHEMBL6133826 0.87 CLK1 (0.36) KMT2AMAPTNPSR1ADORA2AADORA1
SCHEMBL6134855 0.87 KDM5B (0.36) LMNATP53ADORA2AADORA1EGFR
SCHEMBL6134324 0.85 ADORA1 (0.47) KMT2AADORA2AADORA1
SCHEMBL6134686 0.85 GFER (0.43) GFERKMT2ACA12CA1CA2
SCHEMBL6133855 0.85 ADORA2A (0.48) MAPTNPSR1LMNALRRK2ADORA2A
SCHEMBL6133581 0.84 ADORA1 (0.49) GFERKMT2AMAPTMAPK10TP53
SCHEMBL6135805 0.84 ADORA1 (0.37) MAPTNPSR1LMNALRRK2ADORA2A
SCHEMBL6134941 0.84 CDC7 (0.38) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed
WO-2003057689-A1 AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 GFER 812/4885KMT2A 1769/4885CA12 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.